• Hemostasis at the target blood oozing site [ Time Frame: within 3 minutes ]
  Proportion of participants achieving hemostasis within 3 minutes after HLBLS-200 application
• Adverse Event [ Time Frame: up to 12 weeks ]
  Incidence of Adverse Event after application of HLBLS-200

• Hemostasis at the target blood oozing site [ Time Frame: within 10 minutes ]
  Proportion of participants achieving hemostasis within 5, 7, 10 minutes after HLBLS-200 application
• Time to hemostasis [ Time Frame: within 10 minutes ]
  Time to hemostasis at the target blood oozing site after HLBLS-200 application
• Proportion of participants with abnormal laboratory value [ Time Frame: up to 12 weeks ]
  Safety evaluation
• Proportion of participants with operation site bleeding after hepatectomy [ Time Frame: up to 12 weeks ]
  Hemorrhage at the operation site

Patients scheduled for hepatic resection who voluntarily agree to participate the study will be recruited for the screening procedures.

Patients who meet the eligibility criteria will be assigned to the study. Subjects will receive HLBLS-200 as a supplementary hemostatic technique for oozing hemorrhage which can be occurred during hepatic resection.

A dose of HLBLS-200 based on the area of liver resection will be applied and time to hemostasis of blood oozing will be evaluated.

Patients will be followed for 12 weeks after application of HLBLS-200 to monitor any adverse event.

Study objective:

1. To investigate the safety of HLBLS-200 application.
2. To explore hemostatic function of HLBLS-200 in patients receiving hepatectomy.

Inclusion Criteria: (during screening period)

• Subject aged between 18 and 80 years old and scheduled for non-emergent hepatic resection.
• Subject is willing to provide written consent and able to comply with study procedures.
• Female subject of childbearing potential who is willing to use an adequate method of contraception or to be abstinent during the course of the study.

Inclusion Criteria: (during hepatectomy)

• Subjects who need to receive additional hemostatic treatment for blood oozing at the resection site after application of primary hemostatic methods.

Exclusion Criteria: (during screening period)

• Subject with a history of bleeding disorder, platelet disorder or bone marrow disorder.
• Platelet count < 50 X 10^9/L or International normalized ratio > 2.
• Subject who received any drug affecting hemorrhage and/or hemostasis such as anticoagulants, antiplatelet agents or thrombolytic agent within 2 weeks prior to hepatectomy.
• Subject with a history of hypersensitivity to the substance of the investigational device.
• Creatinine clearance < 30mL/min
• Aspartate transaminase or alanine aminotransferase ≥ 3.0 X upper limit of normal.
• Subject with a suspected disorder of decrease in fibrinolytic activity such as disseminated intravascular coagulation.
• Subject with a history of alcohol or drug abuse.
• Pregnant or lactating women
• Subject who have participated in other clinical trial and have received investigation drugs or devices within 4 weeks prior to participation in the study.
• Subject who were judged by the investigator as inadequate for participation in the study.

Exclusion Criteria: (during hepatectomy)

• Subject with following major bleeding (e.g. spurting hemorrhage, hemorrhage from hepatic veins) despite application of primary hemostatic methods
• Subject who is deemed to need anticoagulant treatment within 48 hours of hepatectomy.
• For other reason, subject who were judged by the investigator as inadequate for participation in the study.